Published On: 6/11/2024
EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at EASL 2024 titled “A Prospective Assessment of Disease Progression Impact on Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.”
Focusing on metabolic dysfunction-associated stereotactic liver disease (MASLD), the study investigated disease progression impact on patient-reported outcomes (PROs) and highlights the increased burden on patients as the disease advances. Watch this video presentation by Dr. Sanyal highlighting the important study:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
04/03/2025
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data -
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life -
03/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry) -
03/07/2025
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies -
02/20/2025
Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data